Latest Period
Q1 2026
Security Snapshot
Inhibrx Biosciences, Inc. - Common Stock, par value $0.0001 per share (INBX) Institutional Ownership
CUSIP: 45720N103
13F Institutional Holders and Ownership History from Q2 2024 to Q1 2026
Institutions Reporting
134
Shares (Excl. Options)
12,713,962
Price
$67.23
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.0001 per share
- Symbol
- INBX on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 12,713,962
- Total 13F value
- $854,579,371
- Portfolio coverage rank
- 0%
- Share change
- -220,946
- Value change
- -$23,513,581
- Number of holders
- 134
- Shares outstanding
- 14,630,961
- SEC-reported price per share
- $129.06
- Insider filing price
- $129.06
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- INBX - Inhibrx Biosciences, Inc. - Common Stock, par value $0.0001 per share is tracked under CUSIP 45720N103.
- 134 institutions reported positions in Q1 2026.
- 6 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 139 to 134 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $1,009,450,205 to $854,579,371.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 134 institutions filings for Q1 2026.
Security key
45720N103
Latest holder period
Q1 2026
13F holders
134
13D/G owners
6
CIK / CUSIP context first
Open Q1 2026 holders
INBX full holder history
Inhibrx Biosciences, Inc. SEC filings
Inhibrx Biosciences, Inc. company facts
Inhibrx Biosciences, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 45720N103:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
6
Security
INBX
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| VIKING GLOBAL INVESTORS LP | 10% | 0% | $110,017,116 | +$528,772 | 1,461,633 | +0.48% | VIKING GLOBAL INVESTORS LP | 31 Mar 2026 |
| PERCEPTIVE ADVISORS LLC | 10% | $109,977,373 | 1,461,105 | Perceptive Advisors LLC | 31 Mar 2026 | |||
| MORGAN STANLEY | 7.9% | $84,668,884 | 1,155,416 | Morgan Stanley | 31 Dec 2025 | |||
| Kayyem Jon Faiz | 7.9% | $13,765,571 | 1,149,046 | Jon Faiz Kayyem | 03 Jun 2024 | |||
| Lappe Mark | 6.4% | $11,086,448 | 925,413 | Mark Lappe | 12 Sep 2024 | |||
| BlackRock, Inc. | 5.3% | +12% | $60,682,270 | +$6,933,198 | 768,130 | +13% | BlackRock, Inc. | 31 Dec 2025 |
As of 31 Mar 2026, 134 institutional investors reported holding 12,713,962 shares of Inhibrx Biosciences, Inc. - Common Stock, par value $0.0001 per share (INBX). This represents 87% of the company’s total 14,630,961 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
78%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | 9.9% | 1,442,707 | -0.69% | 1.9% | $96,993,192 |
| VIKING GLOBAL INVESTORS LP | 9.8% | 1,437,705 | 0% | 0.27% | $96,656,907 |
| MORGAN STANLEY | 8.6% | 1,263,078 | +8.2% | 0.01% | $84,916,798 |
| Sanofi | 7.9% | 1,157,926 | 0% | 23% | $77,847,365 |
| HighTower Advisors, LLC | 5.9% | 870,200 | -0.04% | 0.06% | $58,503,546 |
| BlackRock, Inc. | 5.5% | 798,898 | +2.8% | 0% | $53,709,896 |
| STATE STREET CORP | 3.8% | 550,845 | +47% | 0% | $37,033,309 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.3% | 486,422 | 0% | 0% | $32,702,151 |
| Sofinnova Investments, Inc. | 2.8% | 406,029 | -11% | 1.4% | $27,297,330 |
| Capital Research Global Investors | 2.7% | 392,847 | -6.8% | 0% | $26,411,104 |
| Woodline Partners LP | 2.6% | 384,433 | +176% | 0.1% | $25,845,431 |
| MILLENNIUM MANAGEMENT LLC | 2.2% | 327,860 | +19% | 0.02% | $22,042,028 |
| PFM Health Sciences, LP | 2.1% | 305,431 | +15% | 2.2% | $20,534,126 |
| Schonfeld Strategic Advisors LLC | 1.7% | 254,827 | +19% | 0.14% | $17,132,019 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.6% | 231,509 | +2.4% | 0% | $15,568,109 |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | 1.2% | 170,700 | -35% | 0.02% | $11,476,161 |
| SummitTX Capital, L.P. | 0.94% | 137,821 | +66% | 0.3% | $9,265,706 |
| Soleus Capital Management, L.P. | 0.9% | 131,000 | +424% | 0.36% | $8,807,130 |
| CAPITOLIS LIQUID GLOBAL MARKETS LLC | 0.85% | 125,000 | 0% | 0.05% | $8,403,750 |
| CDC Financial, Inc. | 0.85% | 124,530 | +12% | 6.9% | $8,372,152 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.67% | 97,873 | -67% | 0.01% | $6,580,002 |
| GOLDMAN SACHS GROUP INC | 0.65% | 95,074 | -5.5% | 0% | $6,391,826 |
| NORTHERN TRUST CORP | 0.64% | 93,696 | +5.9% | 0% | $6,299,182 |
| D. E. Shaw & Co., Inc. | 0.53% | 77,437 | -37% | 0% | $5,206,090 |
| KENNEDY CAPITAL MANAGEMENT LLC | 0.5% | 72,812 | +1.9% | 0.1% | $4,895,151 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
8
Latest
Q1 2026
Rows shown
1-8 of 8
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 12,713,962 | $854,579,371 | -$23,513,581 | $67.23 | 134 |
| 2025 Q4 | 12,777,957 | $1,009,450,205 | +$184,334,509 | $79.00 | 139 |
| 2025 Q3 | 10,497,334 | $353,550,847 | +$6,764,063 | $33.68 | 101 |
| 2025 Q2 | 10,435,616 | $148,917,132 | -$5,468,523 | $14.27 | 87 |
| 2025 Q1 | 10,790,279 | $150,950,613 | -$5,227,676 | $13.99 | 92 |
| 2024 Q4 | 11,165,626 | $171,927,470 | +$10,221,839 | $15.40 | 101 |
| 2024 Q3 | 8,897,409 | $139,328,871 | -$10,813,194 | $15.66 | 95 |
| 2024 Q2 | 9,650,613 | $136,747,433 | +$136,582,849 | $14.17 | 86 |